mannitol + methylprednisolone + immunoglobulin

This is a **combination drug regimen** consisting of mannitol, methylprednisolone, and immunoglobulin (typically intravenous immunoglobulin, IVIG). - **Mannitol** is an osmotic diuretic that reduces intracranial pressure and edema. - **Methylprednisolone** is a synthetic glucocorticoid corticosteroid that acts as an anti-inflammatory and immunosuppressive agent by binding the glucocorticoid receptor, inhibiting pro-inflammatory cytokines and cell recruitment. - **Immunoglobulin** (usually IVIG) is a biologic derived from pooled human plasma; it provides passive immunity or immune modulation, binding autoantibodies and modulating Fc receptor and cytokine responses. The combination has been reported for use in treatment of acute demyelinating conditions of the central nervous system, such as **acute disseminated encephalomyelitis (ADEM)**, neurological autoimmune/inflammatory diseases, and has also been trialed alongside other agents in severe CNS infections[1][5][2][4]. Mechanistically, the regimen aims to reduce CNS inflammation and edema (mannitol), suppress abnormal immune responses (methylprednisolone), and modulate or replace dysfunctional immune components (immunoglobulin)[1][5][2][4].

Other names

mannitol + methylprednisolone + immunoglobulin